The New South Wales government has pushed to consolidate a class action accusing it of failing to pay overtime hours to junior doctors with multiplying industrial actions filed by Australian Salaried Medical Officers’ Federation.
Victoriaās Emergency Services Telecommunications Authority may be hit with a class action over alleged systemic failures in its ambulance call handling operations that may have led to at least 15 deaths.
An IP Australia delegate has rejected German drug maker Ever Neuro Pharma’s claim that extensive experimental evidence was needed to prove the usefulness of a Parkinson’s drug developed by UK-based Britannia Pharmaceuticals.
The applicants in a class action against The Cosmetic Institute and twelve doctors over allegedly “incompetent” breast augmentation surgery have won court approval to expand their case to allege misleading and deceptive conduct and breaches of the consumer guarantees in the Australian Consumer Law.
Regenerative medicine company Mesoblast is facing another class action over claims it misled shareholders about the potential application of a developmental stem cell product to treat terminally ill children.
The Full Federal Court has rejected German drug maker Boehringer Ingelheim’s appeal of ruling that shot down its opposition to Merck Sharp & Dohme’s patent application for an injectable anti-parasite drug for livestock.
The High Court has granted special leave to a cosmetic company to challenge a judgment finding it infringed Botox maker Allergan’s trade marks by marketing its topical creams as Botox alternatives.
Ramsay Health Care Australia has been let off the hook for using emails subpoenaed in a defamation case between two feuding surgeons at one of its hospitals, with a judge accepting that an in-house lawyer was “mortified” by her mistake and was “drowning in work” at the time.
Pharmaceutical giant Pfizer has fired off a lawsuit against four drug companies for allegedly infringing one of its patents for biologic Enbrel by selling a biosimilar of the blockbuster arthritis drug in Australia.
Bayer has dropped its appeal to a ruling that quashed an extension for its patent covering an oral contraceptive, after the Full Court dealt drug makers a blow in two separate cases on how patent term extensions should be calculated.